BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2019 10:34:38 AM | Browse: 1256 | Download: 2669
 |
Received |
|
2018-11-20 02:26 |
|
Peer-Review Started |
|
2018-11-20 02:50 |
|
First Decision by Editorial Office Director |
|
2018-12-07 17:32 |
|
Return for Revision |
|
2018-12-12 09:50 |
|
Revised |
|
2018-12-17 03:00 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-01-03 11:27 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-01-04 00:10 |
|
Articles in Press |
|
2019-01-04 00:10 |
|
Edit the Manuscript by Language Editor |
|
2019-01-16 16:45 |
|
Typeset the Manuscript |
|
2019-05-14 02:19 |
|
Publish the Manuscript Online |
|
2019-05-15 10:34 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Integrative & Complementary Medicine |
| Manuscript Type |
Basic Study |
| Article Title |
Qingjie Fuzheng Granules inhibits colorectal cancer cells growth by PI3K/AKT and ERK pathways
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong Yang, Jian-Xin Liu, Hai-Xia Shang, Shan Lin, Jin-Yan Zhao and Jiu-Mao Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Project Funding of the Scientific Research Foundation of Traditional Chinese Medicine of Fujian Provincial Health and Family Planning Commission |
2017FJZYZY203 |
| the Training of Young and Middle-Aged Backbone Personnel of Fujian Provincial Health and Family Planning Commission |
2016-ZQN-67 |
|
| Corresponding Author |
Jiu-Mao Lin, PhD, Academic Fellow, Academic Research, Senior Research Fellow, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, 1 Qiuyang Road, Minhou Shangjie, Fuzhou 350122, Fujian Province, China. linjiumao@fjtcm.edu.cn |
| Key Words |
Qingjie Fuzheng Granules; Colorectal cancer; Proliferation; Apoptosis; PI3K/AKT; ERK |
| Core Tip |
To study the effect and mechanism of Qingjie Fuzheng Granules (QFG) on colorectal cancer (CRC) cells, we measured cell viability and cytotoxicity by performing MTT and LDH assays; evaluated the role of QFG in cell proliferation by conducting colony formation, cell cycle and western blot assays; evaluated the role of QFG in cell apoptosis by assessing Hoechst 33258, Annexin-V/PI and western blot assays. Furthermore, the activation of PI3K/AKT and ERK signaling pathways was examined using the western blot assay to investigate the possible mechanism. All results demonstrated that QFG inhibited CRC cells growth by suppressing PI3K/AKT and ERK signaling pathways. |
| Publish Date |
2019-05-15 10:34 |
| Citation |
Yang H, Liu JX, Shang HX, Lin S, Zhao JY, Lin JM. Qingjie Fuzheng Granules inhibits colorectal cancer cells growth by PI3K/AKT and ERK pathways. World J Gastroenterol Oncol 2019; 11(5): 377-392 |
| URL |
https://www.wjgnet.com/1948-5204/full/v11/i5/377.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v11.i5.377 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
